Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Receives IMVAMUNE Smallpox Vaccine Order from Biomedical Advanced Research and Development Authority; Confirms FY 2013 Revenue and Result before Tax Guidance
Bavarian Nordic A/S announced that BARDA (Biomedical Advanced Research and Development Authority), a division of the U.S. Department of Health & Human Services (HHS), has awarded the Company a contract valued at up to USD 228 million for the continued supply of the Company's IMVAMUNE smallpox vaccine. The first USD 110 million of the new order is secured, and the remaining portion will be secured based on availability of funds in 2014. Under the agreement, payments of additional USD 37 million will be received, associated with the delivery of the original 20 million dose order. Additionally, Bavarian Nordic A/S announced that its fiscal year 2013 revenue guidance remains unchanged at the level of DKK 1,100 million. The Company also continues to expect break-even result before tax for the fiscal year 2013. The cash preparedness at year-end is expected to be roughly DKK 600 million. According to I/B/E/S Estimates analysts on average are expecting the Company to report revenue of DKK 1,095.80 million for the fiscal year 2013.
Latest Developments for Bavarian Nordic A/S
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC updates on conditional subscription by Regent Pacific Group Limited
- Lansen Pharmaceutical Holdings Ltd recommends interim dividend
- Eagle Veterinary Technology announces rights issue
- R&I affirms Takeda Pharmaceutical Co Ltd's rating at "AA+" and announces negative outlook
- Share this
- Digg this